Akanji A O, Osifo E, Kirk M, Hockaday T D
Sheikh Rashid Diabetes Unit, Radcliffe Infirmary, Oxford, UK.
Metabolism. 1993 Apr;42(4):426-34. doi: 10.1016/0026-0495(93)90098-9.
Blood levels of intermediary metabolites were measured and indirect calorimetry was performed in 10 otherwise healthy, non-insulin-dependent diabetic (NIDDM) patients before, during, and after 30 minutes of moderate exercise on three occasions in random order at weekly intervals with (1) heparin treatment to increase preexercise plasma nonesterified fatty acid (NEFA) levels (HEPARIN); (2) acipimox, a nicotinic acid analogue, to reduce preexercise plasma NEFA levels (ACIPIMOX); and (3) no manipulation of preexercise plasma NEFA levels (NIL). With ACIPIMOX, preexercise blood levels were significantly reduced for NEFAs and glycerol (P < .01) and marginally reduced for acetoacetate and 3-hydroxybutyrate (NS) compared with preexercise levels for the other two treatments; these low levels seen with acipimox treatment increased only slightly during exercise and the postexercise period. Plasma NEFA levels increased by approximately 150% (P < .001) with HEPARIN at the same times. The levels of ketone bodies during either NIL or HEPARIN increased rapidly postexercise by approximately 90% to 110% for both acetoacetate and 3-hydroxybutyrate (both P < .01). Plasma insulin levels tended to be lowest (despite similar plasma glucose levels during the three treatments) with ACIPIMOX, while growth hormone (hGH) and, perhaps, noradrenaline levels were highest both during and after exercise. The respiratory quotient (RQ) was highest with ACIPIMOX (P < .05 for exercise and postexercise periods compared with the other two treatments), which, compared with NIL, reduced fat oxidation by 27% and 60% and increased carbohydrate oxidation by 29% and 74% during and after exercise, respectively (all P < .05). These changes in substrate oxidation due to ACIPIMOX were almost opposite to those observed with HEPARIN.(ABSTRACT TRUNCATED AT 250 WORDS)
在10名其他方面健康的非胰岛素依赖型糖尿病(NIDDM)患者中,在每周间隔随机进行的三次中等强度运动的前、中、后30分钟,测量中间代谢产物的血药浓度并进行间接测热法。运动方案如下:(1)肝素治疗以提高运动前血浆非酯化脂肪酸(NEFA)水平(肝素组);(2)阿西莫司,一种烟酸类似物,以降低运动前血浆NEFA水平(阿西莫司组);(3)不干预运动前血浆NEFA水平(空白组)。与其他两种治疗的运动前水平相比,阿西莫司组运动前NEFA和甘油的血药浓度显著降低(P < 0.01),乙酰乙酸和3-羟基丁酸的血药浓度略有降低(无统计学意义);阿西莫司治疗时的这些低水平在运动期间和运动后仅略有增加。肝素组运动时血浆NEFA水平同时增加约150%(P < 0.001)。空白组或肝素组运动后酮体水平迅速增加,乙酰乙酸和3-羟基丁酸均增加约90%至110%(均P < 0.01)。阿西莫司组血浆胰岛素水平往往最低(尽管三种治疗期间血浆葡萄糖水平相似),而生长激素(hGH)以及运动期间和运动后去甲肾上腺素水平最高。呼吸商(RQ)在阿西莫司组最高(与其他两种治疗相比,运动期间和运动后P < 0.05),与空白组相比,运动期间和运动后脂肪氧化分别减少27%和60%,碳水化合物氧化分别增加29%和74%(均P < 0.05)。阿西莫司引起的底物氧化变化几乎与肝素组观察到的相反。(摘要截断于250字)